Comparative Pharmacology
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 180.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 180.
GASTROGRAFIN vs OMNIPAQUE 180
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent